You are here:
Publication details
Radiofrekvenční ablace nádorů ledvin
Title in English | RADIOFREQUENCY ABLATION OF RENAL TUMOURS |
---|---|
Authors | |
Year of publication | 2012 |
Type | Article in Periodical |
Magazine / Source | Urologické listy |
MU Faculty or unit | |
Citation | |
Field | Other medical specializations |
Keywords | renal cell carcinoma; small renal mass; radiofrequency ablation; miniinvasive therapy; nephron-sparing; surgery cryotherapy; biopsy |
Attached files | |
Description | An increasing incidence of localized renal cancer during the last three decades and the mortality of this disease has triggered the evaluation of current treatment modalities. The standard therapy for small focal lesions is surgical excision with the aim of sparing the renal parenchyma. Urologists are continuously searching for new alternative methods to substitute classical surgical treatment. They are searching for less aggressive approaches, posing less of a burden to the patient and methods, which can be used in conditions in which the classical or laparoscopic approach is associated with undesirable burden. Alternatives to the surgical treatment of small renal masses include methods, which are based on different physical principles of tissue destruction. These methods can be applied either laparoscopically or percutaneously. The most frequently used methods in clinical practice include radiofrequency ablation and cryoablation. Also other methods are being tested, such as high intensity focused ultrasound, microwave thermotherapy, interstitial photon radiation and laser interstitial ablation. Efficacy of these novel approaches should be comparable to classical surgery. With further improvement of these techniques the long-term results, their benefit and disadvantages are evaluated and new evidence is being collected regarding the efficacy of individual techniques under individual conditions. The alternative, less invasive methods seem to be solution in selected cohorts of high-risk patients, allowing to reduce their morbidity. |